Recent advances of bispecific antibodies in solid tumors

@article{Yu2017RecentAO,
  title={Recent advances of bispecific antibodies in solid tumors},
  author={Shengnan Yu and Anping Li and Qian Liu and Xun Yuan and Hanxiao Xu and D. Jiao and R. Pestell and Xinwei Han and Kongming Wu},
  journal={Journal of Hematology \& Oncology},
  year={2017},
  volume={10}
}
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific antibody (BsAb) is attracting more and more attention as a novel strategy of antitumor immunotherapy. BsAb not only offers an effective linkage between therapeutics (e.g., immune effector cells, radionuclides) and targets (e.g., tumor cells) but also simultaneously blocks two different oncogenic mediators. In recent decades, a… Expand
Bispecific antibodies in cancer immunotherapy
T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances
A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma
Targeting Solid Tumors Using CD3 Bispecific Antibodies
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 168 REFERENCES
Advances in bispecific biotherapeutics for the treatment of cancer.
A novel bispecific antibody, BiSS, with potent anti-cancer activities
Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
Clinical experience with CD64-directed immunotherapy. An overview
  • R. Curnow
  • Medicine
  • Cancer Immunology, Immunotherapy
  • 1997
A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
Alternative molecular formats and therapeutic applications for bispecific antibodies.
Targeting T cells to tumor cells using bispecific antibodies.
...
1
2
3
4
5
...